Africa and Middle East Cardiovascular Epidemiological Study

CompletedOBSERVATIONAL
Enrollment

4,386

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
ObesitySmokingDyslipidemiaDiabetes MellitusHypertension
Trial Locations (73)

1000

Pfizer Investigational Site, Tunis

1100

Pfizer Investigational Site, Zaghouan

1685

Pfizer Investigational Site, Halfway House

2073

Pfizer Investigational Site, Aryanah

3013

Pfizer Investigational Site, Sfax

4010

Pfizer Investigational Site, Bouficha

4013

Pfizer Investigational Site, Messaadine

4091

Pfizer Investigational Site, Sydenham, Durban

Pfizer Investigational Site, Kwa-Zulu Natal

6000

Pfizer Investigational Site, Bejaja

7700

Pfizer Investigational Site, Rondebosch

11584

Pfizer Investigational Site, Riyadh

13000

Pfizer Investigational Site, Tlemcen

16015

Pfizer Investigational Site, Algiers

17000

Pfizer Investigational Site, Djelfa

20000

Pfizer Investigational Site, Saïda

48000

Pfizer Investigational Site, Relizane

60401

Pfizer Investigational Site, Chongoria

Unknown

Pfizer Investigational Site, Laghouat

Pfizer Investigational Site, M'Sila

Pfizer Investigational Site, Tébessa

Pfizer Investigational Site, Yaoundé

Pfizer Investigational Site, Douala

Pfizer Investigational Site, Bafoussam

Pfizer Investigational Site, Mbandjok

Pfizer Investigational Site, Njombé

Pfizer Investigational Site, Okoa

Pfizer Investigational Site, Alexandria

Pfizer Investigational Site, Cairo

Pfizer Investigational Site, Shiben Al Kom

Pfizer Investigational Site, Tanta

Pfizer Investigational Site, Accra

Pfizer Investigational Site, Jachie-Ashanti

Pfizer Investigational Site, Kumasi

Pfizer Investigational Site, Sogakope V/R

Pfizer Investigational Site, Takoradze

Pfizer Investigational Site, Amman

Pfizer Investigational Site, Irbid

Pfizer Investigational Site, Salt

Pfizer Investigational Site, Adailiya

Pfizer Investigational Site, Al Faḩāḩīl

Pfizer Investigational Site, Kuwait City

Pfizer Investigational Site, Mishrif

Pfizer Investigational Site, Qadesya

Pfizer Investigational Site, Yarmouk

Pfizer Investigational Site, Jbeil, Lebanon

Pfizer Investigational Site, Beirut

Pfizer Investigational Site, Jounieh

Pfizer Investigational Site, Tripoli

Pfizer Investigational Site, Abuja, FCT

Pfizer Investigational Site, Abuja, Garki

Pfizer Investigational Site, Calabar

Pfizer Investigational Site, Enugu

Pfizer Investigational Site, Keffi, Nassarawa

Pfizer Investigational Site, Dammam

Pfizer Investigational Site, Jeddah

Pfizer Investigational Site, Mecca

Pfizer Investigational Site, Riyadh

Pfizer Investigational Site, Yanbu

Pfizer Investigational Site, Dakar

Pfizer Investigational Site, Dakar

Pfizer Investigational Site, Kedoungou

Pfizer Investigational Site, Kébémer

Pfizer Investigational Site, Saint-Louis

Pfizer Investigational Site, Ziguinchor

Pfizer Investigational Site, Abu Dhabi

Pfizer Investigational Site, Al Ain City

Pfizer Investigational Site, Dubai

Pfizer Investigational Site, Ras Al Khaima

00508

Pfizer Investigational Site, Nairobi

0600

Pfizer Investigational Site, Mokopane

0742

Pfizer Investigational Site, Sheshego

0122

Pfizer Investigational Site, Mamelodi East

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01243138 - Africa and Middle East Cardiovascular Epidemiological Study | Biotech Hunter | Biotech Hunter